Video

Current Treatment Landscape for HER2+ Breast Cancer

Author(s):

Ruth O'Regan, MD, University of Rochester Medical Center,Joyce O'Shaugnessy, MD, Texas Oncology

Breast cancer experts discuss the evolution of HER2-targeted treatments, including margetuximab, trastuzumab, tucatinib, and neratinib, along with unmet needs in patients with HER2+ breast cancer.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Alberto Montero, MD, MBA, CPHQ
Melanie A. Sheen, MD
Kelly E. McCann, MD, PhD, assistant professor, breast medical oncologist, UCLA
Coy Heldermon, MD, PhD
Kevin Kalinsky, MD, MS, discusses the potential to switch CDK4/6 inhibitors in HR-positive metastatic breast cancer.
Dr Tolaney on Considerations for Adjuvant CDK4/6 Inhibitors in HR+/HER2-Negative Breast Cancer
Icro Meattini, ​MD, an associate professor in the Department of Clinical and Experimental Biomedical Sciences at the University of Florence; as well as a clinical oncologist in the Radiation Oncology Unit in the Oncology Department and head of the Breast Unit and Breast Cancer Multidisciplinary Team at Florence University Hospital
Angela Jain, MD
Related Content
Tanya Gupta, MD
March 19th 2025

Adjuvant CDK4/6 Inhibitors Lay a Solid Treatment Foundation in HR+, HER2– Breast Cancer

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

The top 5 OncLive videos of the week cover insights in colorectal cancer, myeloma, HER2+ breast cancer, and KRAS G12X+ pancreatic ductal adenocarcinoma.
March 16th 2025

Five Under 5: Top Oncology Videos for the Week of 3/9

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib
March 14th 2025

2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib

Vepdegestrant in Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 11th 2025

Vepdegestrant Hits PFS End Point in ESR1-Mutated, ER+/HER2– Metastatic Breast Cancer